Next Article in Journal
Molecular Characterization of XX Maleness
Previous Article in Journal
Anti-Inflammatory and Antioxidant Properties of Dehydrated Potato-Derived Bioactive Compounds in Intestinal Cells
Previous Article in Special Issue
Encapsulation of Lovastatin in Zein Nanoparticles Exhibits Enhanced Apoptotic Activity in HepG2 Cells
Open AccessReview

siRNA Conjugated Nanoparticles—A Next Generation Strategy to Treat Lung Cancer

Department of Radiologic Sciences, Faculty of Health Sciences, American University of Science and Technology (AUST), Beirut, Lebanon
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(23), 6088; https://doi.org/10.3390/ijms20236088
Received: 30 July 2019 / Revised: 16 August 2019 / Accepted: 19 August 2019 / Published: 3 December 2019
Despite major progress in both therapeutic and diagnostic techniques, lung cancer is still considered the leading cause of cancer mortality in the world due to the ineffectiveness of the classical treatments used nowadays. Luckily, the discovery of small interfering RNA (siRNA) planted hope in the hearts of scientists and patients worldwide as a new breakthrough in the world of oncology and a robust tool for finally curing cancer. However, the valuable siRNA must be protected and preserved to ensure the effectiveness of this gene therapy, thus nanoparticles are gaining more attention than previous years as the optimal carriers for this fragile molecule. siRNA-loaded nanoparticles are being extensively investigated to find the appropriate formulation, combination, and delivery route with one objective in mind—successfully overcoming all possible limitations shown in clinical studies and making full use of this novel technique to become the next generation treatment to wipe out many chronic diseases, including cancer. In this review, the benefits of using siRNA and nanoparticles in lung cancer treatment will be globally reviewed before discussing why and how nanoparticles and siRNA can be combined to achieve an efficient treatment of lung cancer for prospective clinical applications. View Full-Text
Keywords: lung cancer; siRNA; nanoparticles; drug delivery systems; diagnosis and therapy lung cancer; siRNA; nanoparticles; drug delivery systems; diagnosis and therapy
Show Figures

Figure 1

MDPI and ACS Style

Itani, R.; Al Faraj, A. siRNA Conjugated Nanoparticles—A Next Generation Strategy to Treat Lung Cancer. Int. J. Mol. Sci. 2019, 20, 6088.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop